User login
Key clinical point: Red blood cell transfusion independence (TI) among patients with myelodysplastic syndrome (MDS) was associated with longer overall survival and lower risk for acute myeloid leukemia (AML) progression.
Major finding: Risk of death was 61.8% (hazard ratio [HR], 0.382; 95% credible interval [CrI], 0.201-0.666) lower in patients with TI vs. transfusion dependence (TD) and 63.4% (HR, 0.366; 95% CrI, 0.217-0.553) lower in patients who acquired TI through treatment vs. those who did not. Patients with TD vs. TI showed a trend toward worse prognosis and higher risk for AML progression (HR, 0.754; 95% CrI, 0.311-1.811).
Study details: Findings are from a meta-analysis of pooled studies that estimated the effect of transfusion sensitivity on clinical outcomes in patients with MDS.
Disclosures: The study was supported by Bristol-Myers Squibb Company. D Tang reported being an employee and equity holder of Bristol-Myers Squibb. T Schroeder reported being a consultant for Celgene International, a Bristol-Myers Squibb Company. The other authors declared no conflicts of interest.
Source: Lemos MB et al. Eur J Haematol. 2021 Mar 14. doi: 10.1111/ejh.13619.
Key clinical point: Red blood cell transfusion independence (TI) among patients with myelodysplastic syndrome (MDS) was associated with longer overall survival and lower risk for acute myeloid leukemia (AML) progression.
Major finding: Risk of death was 61.8% (hazard ratio [HR], 0.382; 95% credible interval [CrI], 0.201-0.666) lower in patients with TI vs. transfusion dependence (TD) and 63.4% (HR, 0.366; 95% CrI, 0.217-0.553) lower in patients who acquired TI through treatment vs. those who did not. Patients with TD vs. TI showed a trend toward worse prognosis and higher risk for AML progression (HR, 0.754; 95% CrI, 0.311-1.811).
Study details: Findings are from a meta-analysis of pooled studies that estimated the effect of transfusion sensitivity on clinical outcomes in patients with MDS.
Disclosures: The study was supported by Bristol-Myers Squibb Company. D Tang reported being an employee and equity holder of Bristol-Myers Squibb. T Schroeder reported being a consultant for Celgene International, a Bristol-Myers Squibb Company. The other authors declared no conflicts of interest.
Source: Lemos MB et al. Eur J Haematol. 2021 Mar 14. doi: 10.1111/ejh.13619.
Key clinical point: Red blood cell transfusion independence (TI) among patients with myelodysplastic syndrome (MDS) was associated with longer overall survival and lower risk for acute myeloid leukemia (AML) progression.
Major finding: Risk of death was 61.8% (hazard ratio [HR], 0.382; 95% credible interval [CrI], 0.201-0.666) lower in patients with TI vs. transfusion dependence (TD) and 63.4% (HR, 0.366; 95% CrI, 0.217-0.553) lower in patients who acquired TI through treatment vs. those who did not. Patients with TD vs. TI showed a trend toward worse prognosis and higher risk for AML progression (HR, 0.754; 95% CrI, 0.311-1.811).
Study details: Findings are from a meta-analysis of pooled studies that estimated the effect of transfusion sensitivity on clinical outcomes in patients with MDS.
Disclosures: The study was supported by Bristol-Myers Squibb Company. D Tang reported being an employee and equity holder of Bristol-Myers Squibb. T Schroeder reported being a consultant for Celgene International, a Bristol-Myers Squibb Company. The other authors declared no conflicts of interest.
Source: Lemos MB et al. Eur J Haematol. 2021 Mar 14. doi: 10.1111/ejh.13619.